-
Loading metrics
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
- Michael J. Harvey,
- Yi Zhong,
- Eric Morris,
- Jacob N. Beverage,
- Robert S. Epstein,
- Anita J. Chawla
x
- Published: January 24, 2022
- https://doi.org/10.1371/journal.pone.0261336